Status:
UNKNOWN
Clinical Study of 68Ga Labeled HER2 Affibody Analogues
Lead Sponsor:
Xijing Hospital
Conditions:
HER2-positive Breast Cancer and Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily evaluate its diagnosis v...
Detailed Description
6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples ...
Eligibility Criteria
Inclusion
- patients with breast or gastric cancers: diagnosed by MR and ready for surgery
Exclusion
- refuse or cannot endure surgery pregnant women
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05411432
Start Date
June 1 2022
End Date
December 1 2023
Last Update
June 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.